LIST OF TRIALS INCLUDED IN THE NETWORK META-ANALYSIS
"restenosis", "coronary restenosis", "ISR", "in-stent restenosis", "intra-stent restenosis", "insegment restenosis", "percutaneous coronary intervention", "coronary angioplasty", "drug eluting stent", "DES", "bare metal stent", "BMS", "drug eluting balloon", "DEB", "drug coated balloon", "DCB", "brachytherapy", "plain balloon angioplasty", "POBA", "cutting", "rotablator", "rotablation", "rotational atherectomy". Acute MI within the previous month, LVEF <30%, evidence of intraluminal thrombus or dissection, unprotected ostium lesion, missing visualization of the distal lumen after crossing with a guidewire, stents obviously not fully expanded, stents at or directly distal to a bend >45°, stents implanted within the previous 3 months, stents with a classic coil design that might impair QCA.
RESCUT
Angina or ischemia at functional test, ISR length ≤25 mm. ISR in a bifurcated stent, MI <72 hours, concomitant angioplasty in another vessel during the same procedure or <30 days, additional BT after the randomised mechanical treatment of ISR by cutting balloon or conventional balloon, lesion located in an internal mammary artery, saphenous vein bypass graft or unprotected left main coronary artery, known allergy to investigational medications.
RIBS
Angina or objective evidence of myocardial ischemia with ISR, lesions amenable to both interventional strategies, first ISR, ISR length ≤32 mm, vessel >2.5 mm.
Lesions located in severely tortuous or calcified vessels and those presenting as total occlusions, prior stent implantation within the previous month, severe concomitant systemic illness, conditions likely to preclude follow-up angiography.
Ragosta et al.
First ISR occurred within 1 year from initial stent placement. Vessel <2.5 mm, lesions not appropriately treatable by either of the randomised techniques. 
SISR
History of SA or UA or documented silent ischemia, ISR length 15-40 mm, vessel 2.5-3.5 mm, vessel 1 cm distal to the target lesion ≥2.5 mm.
MI <24 hours, LVEF <40%, prior thoracic radiation or intravascular brachytherapy, total occlusions, unprotected left main coronary artery disease with >50% stenosis, treatment of a non-target lesion <30 days or planned after the index study procedure, serum creatinine >2 mg/dL, initial stent placement in the target lesion <4 weeks. /μL, woman of child-bearing potential without a recent negative pregnancy test or lactating, man or woman with planned procreation <3 months, comorbid conditions limiting life expectancy <24 months or that could affect protocol adherence, planned procedure requiring antiplatelet therapy withdrawal <6 months, current participation in other investigational trials.
TAXUS V ISR

INDEED
Diffuse ISR, native coronary artery, angina and documented myocardial ischemia.
MI ≤72 h, serum creatinine >3.0 mg/dL, pregnancy, contraindication to antiplatelet therapy, concomitant serious disease with expected survival of <2 years. 
PEPCAD II
SUPPLEMENTARY FIGURE 3: Major Adverse Cardiac Events (network subanalysis plain balloon-drug-coated balloon-drug-eluting stent).
At network meta-analysis the risk reduction was consistent comparing DCB with PB and DES with PB. Pair-wise Bayesian results were in agreement with standard frequentist comparisons. PB=Plain Balloon; DCB=Drug-Coated Balloon; DES=Drug-Eluting Stent; OR=Odds Ratio; CrI=Credible Interval; CI=Confidence Interval.
SUPPLEMENTARY FIGURE 4: Death (network subanalysis plain balloon-drug-coated balloon-drug-eluting stent).
At network meta-analysis there was a trend favoring DCB and DES as compared with PB. However, the low number of events did not allow for definite conclusions. Pair-wise Bayesian results were in agreement with standard frequentist comparisons. PB=Plain Balloon; DCB=Drug-Coated Balloon; DES=Drug-Eluting Stent; OR=Odds Ratio; CrI=Credible Interval; CI=Confidence Interval.
